Preclinical models for studying tumor autoimmunity reveal new roles for IDO, which may dictate the balance between antitumor and tolerance in response to chemotherapy and cell death.88 In addition, IDO prevents the antitumor effects of T cell-dependent complement deposition, and inhibition of IDO was shown to reactive this process.90–92. The gene discussed is IDO1; the disease is neoplasm.